A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Global Development, Inc.
With
Medivation, Inc.
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Progressive prostate cancer while on androgen deprivation therapy
Castrate testosterone level
Maintenance of surgical or medical castration for duration of study
Radiographically visible metastatic disease
Symptomatic from prostate cancer
Eastern Cooperative Oncology Group (ECOG) 0-2
Life expectancy \>=6 months
You may not be if
Brain metastases or leptomeningeal disease
Prior cytotoxic chemotherapy for prostate cancer
Prior use of ketoconazole or abiraterone acetate or other investigational agent that blocks androgen synthesis or targets androgen receptor
History of seizure or condition that may predispose to seizure
History of loss of consciousness or transient ischemic attack within 12 months
Clinically significant cardiovascular disease
Clareo Health | A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
